Article Content
MarketFlick Insights
At a glance
- •Gold nears $4,500 per ounce, driven by geopolitical tensions.
- •Silver outperforms gold with a 140% increase this year.
- •Stock markets remain subdued as year-end approaches.
- •Novo Nordisk's tablet form of Wegovy boosts its stock.
- •Alzchem extends executive contracts, leading to a share increase.
Market Analysis
The rally in precious metals is showing no signs of slowing down, with both gold and silver reaching new heights. On Tuesday, the price of gold soared to a new record, nearing $4,500 per ounce. Overnight, gold prices increased by up to 1.2%, hitting $4,497.74. This surge is attributed to escalating geopolitical tensions and expectations of further interest rate cuts in the United States. Although gold's price slightly receded, it maintained a level of $4,477, still higher than Monday's close. This marks a continued upward trend since the rally in October. Since the end of 2024, gold prices have surged by over 70%, positioning gold as one of the best-performing asset classes. This year, it is on track for the highest annual gain since 1979, when prices rose by 127%. Silver has outperformed gold, with its price climbing by 140% this year. On Tuesday, silver also reached a record, just shy of the $70 mark at $69.99 per ounce.
Stock Market Performance
While precious metals are seeing significant gains, the stock market remains relatively subdued. Investors are cautious as the year-end approaches, with many having closed their books for the year and the Christmas holidays underway. On Tuesday, the DAX index was up slightly by 0.2% at 24,331 points, and the MDAX saw a modest increase of 0.1% to 30,456 points. The Euro Stoxx 50 remained flat. Despite the quiet in equities, the DAX continues to hold above the critical 24,000-point mark, supported by strong U.S. market cues. The S&P 500 is on track for its eighth consecutive month of gains, having risen by about 17% this year, while the DAX has seen a substantial 22% increase.
Company Developments
In corporate news, Novo Nordisk has made significant strides in the U.S. market. The Danish pharmaceutical giant has received approval to sell its weight-loss drug Wegovy in tablet form, starting in January. This development could capture a larger market segment, catering to patients who avoid injections. As a result, Novo Nordisk's shares jumped over 7%. Conversely, this news negatively impacted Gerresheimer and Schott Pharma, which supply the syringes, with their stocks dropping by 0.8% and 0.7%, respectively. Meanwhile, Alzchem, a specialty chemicals company, announced early extensions of contracts for key executives. CEO Andreas Niedermaier will remain in his position until the end of 2028, and CFO Andreas Lösler's contract has been extended to the end of 2029. This announcement saw Alzchem shares rise by 1.1%. Overall, while the gold and silver markets are experiencing significant growth, the stock market remains cautious, and individual companies are navigating both opportunities and challenges in the current economic landscape.
